Memorial Sloan Kettering angers stakeholders with tepid crisis response
The leading cancer hospital is embroiled in controversy after a leading doctor failed to disclose millions in incentives from drug companies. Can the oncology center win back patients’ trust?
Consumer trust is important in any industry. In health care, it’s essential.
Scandal has rocked Memorial Sloan Kettering Cancer Center, one of the nation’s leading oncology facilities, shredding that trust. Its chief medical officer failed to disclose millions of dollars in incentives and kickbacks he had received from pharmaceutical companies.
The researcher, Dr. José Baselga, a towering figure in the cancer world, is the chief medical officer at Memorial Sloan Kettering Cancer Center in New York. He has held board memberships or advisory roles with Roche and Bristol-Myers Squibb, among other corporations; has had a stake in start-ups testing cancer therapies; and played a key role in the development of breakthrough drugs that have revolutionized treatments for breast cancer.
Become a Ragan Insider member to read this article and all other archived content.
Sign up today
Already a member? Log in here.
Learn more about Ragan Insider.
